Actualités Moberg Pharma Ab (publ) - 0P48 | Actions London Stock Exchange

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients PR Newswire STOCKHOLM...

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98% PR...

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7...

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication PR Newswire STOCKHOLM, Feb. 7...

MOB-015 is recommended for approval in EU: Moberg Pharma

MOB-015 is recommended for approval in EU: Moberg Pharma PR Newswire STOCKHOLM, June 28, 2023 STOCKHOLM, June 28, 2023 /PRNewswire/ -- Moberg...

European marketing authorization application for MOB-015 submitted

European marketing authorization application for MOB-015 submitted PR Newswire STOCKHOLM, March 28, 2022 STOCKHOLM, March 28, 2022 /PRNewswire/...

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application PR Newswire STOCKHOLM...

Moberg Pharma receives approval from the EMA's Paediatric Committee

Moberg Pharma receives approval from the EMA's Paediatric Committee PR Newswire STOCKHOLM, Sept. 22, 2021 STOCKHOLM, Sept. 22, 2021 /PRNewswire/...

Moberg Pharmas Year-end report 2020

Moberg Pharmas Year-end report 2020 PR Newswire STOCKHOLM, Feb. 9, 2021 STOCKHOLM, Feb. 9, 2021 /PRNewswire/ -- Financing for both MOB-015 and...

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex...

New number of shares and votes in Moberg Pharma AB (publ)

New number of shares and votes in Moberg Pharma AB (publ) PR Newswire STOCKHOLM, Jan. 29, 2021 STOCKHOLM, Jan. 29, 2021 /PRNewswire/ -- During...

OncoZenge announces issue of European Patent related to BupiZenge®

OncoZenge announces issue of European Patent related to BupiZenge® PR Newswire STOCKHOLM, Jan. 7, 2021 STOCKHOLM, Jan. 7, 2021 /PRNewswire/...

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

OncoZenge raises MSEK 10 ahead of spin-off and separate listing PR Newswire STOCKHOLM, Dec. 11, 2020 STOCKHOLM, Dec. 11, 2020 /PRNewswire/...

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge PR...

Invitation to market update in Moberg Pharma on November 25th

Invitation to market update in Moberg Pharma on November 25th PR Newswire STOCKHOLM, Nov. 23, 2020 STOCKHOLM, Nov. 23, 2020 /PRNewswire/ -- On...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Moberg Pharma Ab (publ) (0P48)

Votre Hub pour des idées et discussions en direct en temps réel

0P48 Actualités

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is recommended for approval in EU: Moberg Pharma

European marketing authorization application for MOB-015 submitted

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application

Moberg Pharma receives approval from the EMA's Paediatric Committee

Moberg Pharmas Year-end report 2020

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...

New number of shares and votes in Moberg Pharma AB (publ)

OncoZenge announces issue of European Patent related to BupiZenge®

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...

Invitation to market update in Moberg Pharma on November 25th

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Moberg Pharma Ab (publ) (0P48) Actualités

Moberg Pharma Ab (publ) (0P48)

Votre Hub pour des idées et discussions en direct en temps réel

0P48 Actualités

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication

MOB-015 is recommended for approval in EU: Moberg Pharma

European marketing authorization application for MOB-015 submitted

The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration application

Moberg Pharma receives approval from the EMA's Paediatric Committee

Moberg Pharmas Year-end report 2020

Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...

New number of shares and votes in Moberg Pharma AB (publ)

OncoZenge announces issue of European Patent related to BupiZenge®

OncoZenge raises MSEK 10 ahead of spin-off and separate listing

Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...

Invitation to market update in Moberg Pharma on November 25th

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application